Clinical trial
Bexarotene in Treating Patients With Metastatic Breast Cancer
NCT00003752
Study timeline
Study start (unknown)1998-10-01Date precision: month
Registry last updated2013-05-30
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Breast Cancerunresolved
Interventions
bexaroteneDRUG · verified · RxNorm: bexarotene
Sponsors & collaborators
Ligand Pharmaceuticalslead sponsor
Mapped research locations
Los AngelesCalifornia, United States3BostonMassachusetts, United States2ColumbusOhio, United States2JacksonvilleFlorida, United States2New YorkNew York, United States1HoustonTexas, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1MiamiFlorida, United States1San AntonioTexas, United States1NashvilleTennessee, United States1San FranciscoCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00003752 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.